PCSK9 and Stroke: Addressing this question, data from clinical trial FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) have demonstrated a significant relative risk reduction of MI (HR 0.73; 95% Cl 0.65 − 0.82) and stroke (HR 0.79; 95% Cl 0.66 − 0.95) [64].